- Price
- $3.44
- Day
- +0.88%
- Mkt Cap
- $375.63M
- 52W Range
- $2.53 – $5.45
- Volume
- 2.08M
- Beta
- 0.45
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.
Read full article
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. Early safety has been promising with t.
Read full article
[url="]Rocket Pharmaceuticals, Inc.[/url] (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic m
Read full article